Volume : 11, Issue : 05, May – 2024
Title:
ADVANCES IN ASTHMA MANAGEMENT IN PEDIATRICS
Authors :
Hani Abdullah Alhashmi, Fatamh Ali Alsharif, Abdulrahman Ali Walibi, Atheer Mansour Alatawi, Haitham Rasheed Alhaeti, Nojoud Mohammed Alfarhan, Mishaal Hisham Rayees, Sarah Naseemuddin A Khan, Misfer Hassan Misfer Alessa, Abdullah Saeed Abdullah Alshehri, Zahra Ali Abu Alrehi, Amal Habib Al Suliman, Khadija Ali Alkhamis, Salma Ebrahim Alquhaidan, Woroud Mohammed salem alharthi
Abstract :
Asthma is a common condition affecting more than 300 million people around with an incidence rate of 5.3% in children. Asthma requires to be differentiated from other diseases like cystic fibrosis and bronchiectasis. As children have different bodily constitutions compared to adults, the guidelines for pharmacological therapy vary. The use of emerging therapy options eases the burden of emergency department visits. Thus, reviewing the latest advancements and therapy guidelines helps to reduce the associated morbidity and mortality.
Aim of the study: to review the latest methodology for the management of asthma in pediatric patients
Materials and methods: This review is a comprehensive search of PUBMED from the year 2014 to 2024.
Conclusion:Asthma is a disease with a multifactorial etiology, therefore there is a need for a multi-disciplinarian approach to reduce future morbidities in pediatric patients. There is a need for the establishment of recommendations for SMART therapy in children younger than 4 years and further study into the use of biologics.
Keywords: asthma; management; SMART therapy; biologics
Cite This Article:
Please cite this article in press Hani Abdullah Alhashmi et al, Advances In Asthma Management In Pediatrics.,Indo Am. J. P. Sci, 2024; 11 (5).
Number of Downloads : 10
References:
1. Scotney E, Fleming L, Saglani S, Sonnappa S, & Bush A (2023). Advances in the pathogenesis and personalised treatment of paediatric asthma. BMJ medicine, 2(1).
2. Yang C L, Simons E, Foty R G, Subbarao P To T, & Dell S D (2017). Misdiagnosis of asthma in schoolchildren. Pediatric pulmonology, 52(3), 293-302.
3. Martin J, Townshend J, & Brodlie M (2022). Diagnosis and management of asthma in children. BMJ Paediatrics Open, 6(1).
4. Licari A, Castagnoli R, Brambilla I, Marseglia A, Tosca M A, Marseglia G L, & Ciprandi G (2018). Asthma endotyping and biomarkers in childhood asthma. Pediatric allergy, immunology, and pulmonology, 31(2), 44-55.
5. Tripathi P, Awasthi S, & Gao P (2014). ADAM metallopeptidase domain 33 (ADAM33): a promising target for asthma. Mediators of inflammation, 2014(1), 572025.
6. Kuruvilla M E, Lee F E, & Lee G B (2019). Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. Clinical reviews in allergy & immunology, 56(2), 219–233.
7. Ricciardolo F L M, Sprio A E, Baroso A, Gallo F, Riccardi E, Bertolini F, Carriero V, Arrigo E, & Ciprandi G (2021). Characterization of T2-Low and T2-High Asthma Phenotypes in Real-Life. Biomedicines, 9(11), 1684.
8. Esteban-Gorgojo I, Antolín-Amérigo D, Domínguez-Ortega J, & Quirce S (2018). Non-eosinophilic asthma: current perspectives. Journal of asthma and allergy, 11, 267–281.
9. Gibson P G, Simpson J L, Hankin R, Powell H, & Henry R L (2003). Relationship between induced sputum eosinophils and the clinical pattern of childhood asthma. Thorax, 58(2), 116–121.
10. Clin Rev Allergy Immunol. 2019 Apr;56(2):219–233.
11. Global Initiative for Asthma (GINA). (2023). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/
12. Xepapadaki P, Adachi Y, Beltrán C F P, El-Sayed Z A, Gómez R M, Hossny E, & Papadopoulos N G (2023). Utility of biomarkers in the diagnosis and monitoring of asthmatic children. World Allergy Organization Journal, 16(1), 100727.
13. Hossny E, El-Awady H, Bakr S, & Labib A (2009). Vascular endothelial growth factor overexpression in induced sputum of children with bronchial asthma. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 20(1), 89–96.
14. Cuppari C, Manti S, Chirico V, Caruso R, Salpietro V, Giacchi V, Laganà F, Arrigo T, Salpietro C, & Leonardi S (2015). Sputum high mobility group box-1 in asthmatic children: a noninvasive sensitive biomarker reflecting disease status. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 115(2), 103–107.
15. Sol I S, Kim Y H, Park Y A, Lee K E, Hong J Y, Kim M N, Kim Y S, Oh M S, Yoon S H, Kim M J, Kim K W, Sohn M H, & Kim K E (2016). Relationship between sputum clusterin levels and childhood asthma. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 46(5), 688–695.
16. Konradsen J R, Nordlund B, Levänen B, Hedlin G, & Linden A (2016). The cytokine interleukin-26 as a biomarker in pediatric asthma. Respiratory research, 17, 32.
17. Dixon E G, Rugg-Gunn C E, Sellick V, Sinha I P, & Hawcutt D B (2021). Adverse drug reactions of leukotriene receptor antagonists in children with asthma: a systematic review. BMJ paediatrics open, 5(1), e001206. https://doi.org/10.1136/bmjpo-2021-001206
18. van der Woude H J, Boorsma M, Bergqvist P B, Winter T H, & Aalbers R (2004). Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulmonary Pharmacology & Therapeutics, 17(2), 89-95.
19. Smith T, Mills K, Cober M P, Fenn N E, 3rd, Hill C, King M, Pauley J L, Eiland L, Sierra C, & Omecene N E (2024). Updates in the treatment of asthma in pediatrics: A review for pharmacists. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 81(9), e210–e219. https://doi.org/10.1093/ajhp/zxad326
20. Blake K V, & Moon J Y (2023). Asthma. In J. T. DiPiro, G. C. Yee, L. L. Michael Posey, S. T. Haines, T. D. Nolin, & V. L. Ellingrod (Eds.), Pharmacotherapy: A Pathophysiologic Approach (12th ed., pp. [insert page numbers here]). McGraw Hill.
21. Brusselle G G, & Koppelman G H (2022). Biologic Therapies for Severe Asthma. The New England journal of medicine, 386(2), 157–171.
22. Saxena S, Rosas-Salazar C, Fitzpatrick A, & Bacharier L B (2023). Biologics and severe asthma in children. Current opinion in allergy and clinical immunology, 23(2), 111–118.
23. Busse W W, Morgan W J, Gergen P J, Mitchell H E, Gern J E, Liu A H, Gruchalla R S, Kattan M, Teach S J, Pongracic J A, Chmiel J F, Steinbach S F, Calatroni A, Togias A, Thompson K M, Szefler S J, & Sorkness C A (2011). Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. The New England journal of medicine, 364(11), 1005–1015.
24. Pitrez P M, de Souza R G, Roncada C, Heinzmann-Filho J P, Santos G, Pinto L A, Jones M H, & Stein R T (2017). Impact of omalizumab in children from a middle-income country with severe therapy-resistant asthma: A real-life study. Pediatric pulmonology, 52(11), 1408–1413.
25. Corren J, Kavati A, Ortiz B, Colby J A, Ruiz K, Maiese B A, Cadarette S M, & Panettieri R A, Jr (2017). Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review. Allergy and asthma proceedings, 38(4), 250–263.
26. McGregor M C, Krings J G, Nair P, & Castro M (2019). Role of Biologics in Asthma. American journal of respiratory and critical care medicine, 199(4), 433–445.
27. Selby L. & Saglani S (2019). Severe asthma in children: therapeutic considerations. Current opinion in allergy and clinical immunology, 19(2), 132–140.
28. Scotney E, & Saglani S (2020). Diagnosis and Management of Problematic Severe Asthma. Acta medica academica, 49(2), 117–129.
29. Campisi E S, Reyna M E, Brydges M, Dubeau A, Moraes T J, Campisi P, & Subbarao P (2022). Adenotonsillectomy, bronchoscopy and bronchoalveolar lavage in the management of preschool children with severe asthma: pilot study. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology – Head and Neck Surgery, 279(1), 319–326.
30. Shamji M H, Sharif H, Layhadi J A, Zhu R, Kishore U, & Renz H (2022). Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma. The Journal of allergy and clinical immunology, 149(3), 791–801.
31. Đurić-Filipović I, Caminati M, Kostić G, Filipović Đ, & Živković Z (2016). Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis. World journal of pediatrics : WJP, 12(3), 283–290.
32. Avery C, Perrin E M, & Lang J E (2021). Updates to the Pediatrics Asthma Management Guidelines. JAMA pediatrics, 175(9), 966–967.
33. Leung J S (2021). Paediatrics: how to manage acute asthma exacerbations. Drugs in context, 10, 2020-12-7.
34. Indinnimeo L, Chiappini E, Miraglia Del Giudice M, & Italian Panel for the management of acute asthma attack in children Roberto Bernardini (2018). Guideline on management of the acute asthma attack in children by Italian Society of Pediatrics. Italian journal of pediatrics, 44(1), 46.
35. Bekmezian A, Fee C, & Weber E (2015). Clinical pathway improves pediatrics asthma management in the emergency department and reduces admissions. The Journal of asthma : official journal of the Association for the Care of Asthma, 52(8), 806–814.